Acorda Therapeutics Inc
NASDAQ:ACOR
Intrinsic Value
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. [ Read More ]
The intrinsic value of one
ACOR
stock under the Base Case scenario is
180.35
USD.
Compared to the current market price of 0.52 USD,
Acorda Therapeutics Inc
is
Undervalued by 100%.
Acorda Therapeutics Inc's market capitalization is 645.9k USD.
ACOR stock price is 0.52 USD.
ACOR stock price (0.52 USD) is 100% less than its Intrinsic Value (180.35 USD).
ACOR stock price (0.52 USD) is 100% less than its Relative Value (177.1 USD). Open Relative Valuation
ACOR has upside potential of 1 823% compared to the average analyst price target.
Open Wall St Estimates
ACOR has positive three-year average ROE (Return on Equity): 10%. The company is efficient at transforming stockholders' equity into net income.
ACOR's Revenue has dropped by 1% over the past 12 months.
ACOR's ROIC (Return on Invested Capital) has increased in the last 3 years from -7% to -6%, and is approaching profitability.
ACOR's Revenue has been falling by 8% per year for the last 3 years.
ACOR's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -6%.
ACOR's ROE (Return on Equity) has significantly increased in the last 3 years from -49% to 786%.
ACOR has negative Operating Income for the last twelve months.
ACOR has negative Net Income for the last twelve months.
ACOR's ROE (Return on Equity) for the past 12 months is very high and is equal to 786%.
ACOR has positive Gross Profit for the last twelve months.
ACOR has negative three-year average ROIC (Return on Invested Capital): -9%. The company is not efficient at using invested capital to generate operating income.
ACOR's long-term liabilties (266m USD) exceed its long-term assets (109m USD).
ACOR has negative Free Cash Flow for the last twelve months.
ACOR's short-term liabilties (228m USD) exceed its short-term assets (75m USD).
ACOR's D/E (Debt to Equity) is very low and is equal to 0.
ACOR's Altman Z-Score is very low and is equal to -16.65.
ACOR doesn't generate enough operating income (-14m USD) to safely cover interest payments on its debt (12m USD).
Fundamental Analysis
Acorda Therapeutics Inc
Balance Sheet Decomposition
Acorda Therapeutics Inc
| Current Assets | 74.8m |
| Cash & Short-Term Investments | 30m |
| Receivables | 17.3m |
| Other Current Assets | 27.5m |
| Non-Current Assets | 33.7m |
| PP&E | 6.3m |
| Intangibles | 23m |
| Other Non-Current Assets | 4.4m |
| Current Liabilities | 227.8m |
| Accounts Payable | 13.4m |
| Accrued Liabilities | 25.9m |
| Other Current Liabilities | 188.5m |
| Non-Current Liabilities | 38.7m |
| Other Non-Current Liabilities | 38.7m |
Earnings Waterfall
Acorda Therapeutics Inc
|
Revenue
|
117.6m
USD
|
|
Cost of Revenue
|
-15.3m
USD
|
|
Gross Profit
|
102.4m
USD
|
|
Operating Expenses
|
-116m
USD
|
|
Operating Income
|
-13.6m
USD
|
|
Other Expenses
|
-239.2m
USD
|
|
Net Income
|
-252.9m
USD
|
Free Cash Flow Analysis
Acorda Therapeutics Inc
ACOR Profitability Score
Profitability Due Diligence
Acorda Therapeutics Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
Score
Acorda Therapeutics Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.
ACOR Solvency Score
Solvency Due Diligence
Acorda Therapeutics Inc's solvency score is 26/100. The higher the solvency score, the more solvent the company is.
Score
Acorda Therapeutics Inc's solvency score is 26/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ACOR Price Targets Summary
Acorda Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for
ACOR
is 10 USD
.
Ownership
ACOR Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ACOR Price
Acorda Therapeutics Inc
| Average Annual Return | -63.24% |
| Standard Deviation of Annual Returns | 20.49% |
| Max Drawdown | -100% |
| Market Capitalization | 645.9k USD |
| Shares Outstanding | 1 240 000 |
| Percentage of Shares Shorted | 0.66% |
Company Profile
Acorda Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. The company is headquartered in Ardsley, New York and currently employs 118 full-time employees. The company went IPO on 2006-02-10. The firm is focused on developing therapies that restore function and enhance the lives of people with neurological disorders. The firm uses its ARCUS pulmonary delivery system, which is a technology platform designed to deliver medication through inhalation that is used in the development of a variety of inhaled medicines. The Company’s products include INBRIJA (levodopa inhalation powder) and AMPYRA (dalfampridine). INBRIJA is an inhaled levodopa (L-dopa) for intermittent treatment of OFF episodes, also known as OFF periods in people with Parkinson’s disease treated with carbidopa/levodopa regimen. INBRIJA utilizes its ARCUS platform for inhaled therapeutics. AMPYRA (dalfampridine) is an extended-release tablet formulation of dalfampridine as a treatment to enhance walking in patients with multiple sclerosis (MS). Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.
You don't have any saved screeners yet
